Corbus Pharmaceuticals Holdings (STU:3371) ROCE %: -71.49% (As of Mar. 2026)


STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
31 GF Score
Price €7.57
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings ROCE %?

Corbus Pharmaceuticals Holdings STU:3371 +5.36% 31 ROCE % is -71.49% as of Mar. 2026. GuruFocus rates STU:3371 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Corbus Pharmaceuticals Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was -71.49%.

Corbus Pharmaceuticals Holdings  (STU:3371) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Corbus Pharmaceuticals Holdings ROCE % Related Terms

Corbus Pharmaceuticals Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings ROCE % Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -71.73 -50.22 -157.84 -54.54 -50.90

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.10 -56.83 -90.57 -68.59 -71.49
STU:3371
31GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings ROCE % Calculation

Corbus Pharmaceuticals Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-67.071/( ( (148.864 - 11.286) + (143.639 - 17.671) )/ 2 )
=-67.071/( (137.578+125.968)/ 2 )
=-67.071/131.773
=-50.90 %

Corbus Pharmaceuticals Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-84.092/( ( (143.639 - 17.671) + (124.975 - 15.689) )/ 2 )
=-84.092/( ( 125.968 + 109.286 )/ 2 )
=-84.092/117.627
=-71.49 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -71.49% mean?
Corbus Pharmaceuticals Holdings (STU:3371) has a ROCE % of -71.49% as of Mar. 2026.
Is Corbus Pharmaceuticals Holdings' ROCE % too high?
Corbus Pharmaceuticals Holdings' current ROCE % is -71.49%. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' ROCE % compare to AGEN and HURA?
Corbus Pharmaceuticals Holdings' ROCE % of -71.49% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Corbus Pharmaceuticals Holdings's current ROCE % is -71.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (STU:3371) has a current ROCE % of -71.49%. The current ROCE % is -71.49%. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current ROCE % is -71.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score

Get the complete analysis for STU:3371

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.57
Price